Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc. (LYEL) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
lyel · pe ratio · data through Jun 10, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Lyell Immunopharma, Inc.You LYEL | $287M | N/A | — | — |
 AC Immune S.A. ACIU | $222M | N/A | — | -$0.70 |
 Aldeyra Therapeutics, Inc. ALDX | $105M | N/A | — | -$0.56 |
 Allogene Therapeutics, Inc. ALLO | $451M | N/A | — | -$0.87 |
 Amarin Corporation plc AMRN | $294M | N/A | — | -$1.87 |
 Cabaletta Bio, Inc. CABA | $522M | N/A | — | -$1.64 |
 Editas Medicine, Inc. EDIT | $259M | N/A | — | -$1.80 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Lyell Immunopharma, Inc. (LYEL) measures how much investors pay for each dollar of the company's trailing earnings. LYEL's current PE ratio of N/A is calculated by dividing its stock price of $12.31 by its TTM earnings per share of —.
Frequently asked questions
LYEL pe ratio · 6 questionsLYEL's current PE ratio is N/A as of 2026-06-10, based on a stock price of $12.31 and TTM EPS of —. Data sourced from Financial Modeling Prep via LYEL's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Lyell Immunopharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-10